Just how good an investment is the biopharmaceutical sector?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Biotechnology

• Publication date

  2017-12-01

• Fields of study

  Medicine, Business, Economics

• Identifiers
  DOI 10.1038/nbt.4023PMID 29220034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Financing Innovation

  2020cited by this paper
• Sharing R&D Risk in Healthcare Via Fda Hedges

  2017cited by this paper
• Financing Risk and Innovation

  2017cited by this paper
• Competition and R&D Financing Decisions: Evidence from the Biopharmaceutical Industry

  2016cited by this paper
• Text-Based Network Industries and Endogenous Product Differentiation

  2016cited by this paper
• Estimating the biotech sector's contribution to the US economy

  2016cited by this paper
• Cash Holdings, Competition, and Innovation

  2016cited by this paper
• Lessons From Hollywood: A New Approach To Funding R&D

  2016cited by this paper
• Pricing in the Market for Anticancer Drugs.

  2015cited by this paper
• NBER WORKING PAPER SERIES COMPETITION AND R&D FINANCING DECISIONS: THEORY AND EVIDENCE FROM THE BIOPHARMACEUTICAL INDUSTRY

  2015cited by this paper
• Financial Health Economics

  2014cited by this paper
• Investment Cycles and Startup Innovation

  2013cited by this paper
• Can Financial Engineering Cure Cancer

  2013cited by this paper
• Commercializing biomedical research through securitization techniques

  2012cited by this paper
• Product Market Synergies and Competition in Mergers and Acquisitions: A Text-Based Analysis

  2010cited by this paper
• Financial risk of the biotech industry versus the pharmaceutical industry.

  2009cited by this paper
• Financing Innovation and Growth: Cash Flow, External Equity, and the 1990s R&D Boom

  2009cited by this paper
• Reasonable Rx: Solving the Drug Price Crisis

  2008cited by this paper
• Center on Urban and Metropolitan Policy

  2004cited by this paper
• Signs of life: The growth of biotechnology centers in the U.S

  2002cited by this paper
• Disappearing dividends: changing firm characteristics or lower propensity to pay?

  2001cited by this paper
• Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances

  1999cited by this paper
• FINANCIAL DEPENDENCE AND GROWTH

  1998cited by this paper
• Competitive Strategies in the Pharmaceutical Industry

  1996cited by this paper

• A new real option methodology for the quality-by-design pharmaceutical research and development

  2026cites this paper
• Capital Structure Decisions in Swedish Biotechnology Firms: The Role of Intellectual Capital and Innovation Activities

  2025cites this paper
• Acknowledgment analysis: insight into biopharmaceutical company-funded papers and patents

  2025cites this paper
• The R&D productivity challenge: transforming the pharmaceutical ecosystem.

  2025cites this paper
• Are Pharmaceutical Profits Excessive?

  2025cites this paper
• Transmission of Information from Private to Public Markets

  2025cites this paper
• How does news affect biopharma stock prices?: An event study

  2024cites this paper
• Biotech IPOs and Drug Development Disclosure

  2024cites this paper
• Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency ∗

  2023cites this paper
• An elephant in the glasshouse? Trade-offs between acceleration and transformation in COVID-19 vaccine innovation policies

  2023cites this paper
• New Compound Real Option Pricing Method with Lévy Processes for the Quality-by-Design Pharmaceutical R&D

  2023cites this paper
• A Framework for the Fair Pricing of Medicines

  2023cites this paper
• Quantifying the Impact of Impact Investing

  2023cites this paper
• Biothérapies : opportunités et accessibilité

  2023cites this paper
• Risk and return in the biotech industry

  2023cites this paper
• Volatility spillovers, structural breaks and uncertainty in technology sector markets

  2023cites this paper
• 12 A new pharma industrial policy for Europe? Lessons from COVID-19

  2023cites this paper
• curves vary between

  2023cites this paper
• Financial Intermediation and the Funding of Biomedical Innovation: A Review

  2022cites this paper
• Artificial intelligence-based decision support model for new drug development planning

  2022cites this paper
• Which policies for vaccine innovation and delivery in Europe ?

  2022cites this paper
• Biopharmaceutical R&D outsourcing: short-term gain for long-term pain?

  2022cites this paper
• The reaction of sponsor stock prices to clinical trial outcomes: An event study analysis

  2022cites this paper
• The Real Effects of Equity Markets on Innovation

  2022cites this paper
• Financing Biomedical Innovation

  2022influential citation
• How much do the public sector and the private sector contribute to biopharmaceutical R&D?

  2021cites this paper
• Competition and R&D Financing: Evidence From the Biopharmaceutical Industry

  2021cites this paper
• Can Financial Economics Cure Cancer?

  2021cites this paper
• Stock price reaction to the drug development setbacks in the pharmaceutical industry

  2021cites this paper
• The Rich Get Richer and the Poor Get Poorer: Social Media and the Post-IPO Behavior of Investors in Biotechnology Firms: The Relationship with Twitter Volume

  2021cites this paper
• Systematic risk in the biopharmaceutical sector: a multiscale approach

  2021cites this paper
• US biopharmaceutical companies' stock market reaction to the COVID-19 pandemic. Understanding the concept of the ‘paradoxical spiral’ from a sustainability perspective

  2021cites this paper
• Corporate R&D Investments Following Competitors’ Disclosures: Evidence from the Drug Development Process

  2020influential citation
• A multisensor approach for improved protein A load phase monitoring by conductivity‐based background subtraction of UV spectra

  2020cites this paper
• [What is the fair price of innovative therapy?]

  2020cites this paper
• Financial Performance of SDG Mutual Funds Focused on Biotechnology and Healthcare Sectors

  2020influential citation
• Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology.

  2020cites this paper
• The Biotechnology Sector: Therapeutics

  2020cites this paper
• Japanese Pharmaceutical Industry: Recent Perspectives and Areas for Further Research

  2020cites this paper
• Financially adaptive clinical trials via option pricing analysis

  2020cites this paper
• Sustainability in the biopharmaceutical industry: Seeking a holistic perspective.

  2019cites this paper
• The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework

  2019influential citation
• One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry.

  2019cites this paper
• A Hybrid MCDM Model for Evaluating Strategic Alliance Partners in the Green Biopharmaceutical Industry

  2019cites this paper
• Risk and Reward in the Orphan Drug Industry

  2019influential citation
• Find and Replace : R & D Investment Following the Erosion of Existing Products November 2 , 2018

  2018cites this paper
• Financial signal processing: applications to asset-market dynamics and healthcare finance

  2018cites this paper
• Find and Replace: R&D Investment Following the Erosion of Existing Products

  2018cites this paper
• Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries

  2018cites this paper
• Find and Replace: R&D Investment Following the Erosion of Existing Products

  2018cites this paper
• NBER WORKING PAPER SERIES OPTIMAL FINANCING FOR R&D-INTENSIVE FIRMS

  2017influential citation
• Sharing R&D Risk in Healthcare Via Fda Hedges

  2017cites this paper
• Competition and R&D Financing Decisions: Evidence from the Biopharmaceutical Industry

  2016cites this paper
• TRENDS IN FINANCIAL PERFORMANCE AND MARKET CAPITALIZATION OF BIOPHARMACEUTICAL COMPANIES: A LONGITUDINAL STUDY

  year unknowncites this paper